These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6445273)

  • 1. Elevated serum Cu in Hodgkin's disease and inhibitory effects of ceruloplasmin on lymphocyte response in vitro.
    Larsen B; Heron I; Thorling EB
    Eur J Cancer (1965); 1980 Mar; 16(3):415-21. PubMed ID: 6445273
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkin's disease, non-Hodgkin's lymphoma, and nonmalignant lymphadenopathy.
    Margerison AC; Mann JR
    Cancer; 1985 Apr; 55(7):1501-6. PubMed ID: 3978543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ceruloplasmin levels in Hodgkin's disease and malignant lymphomas in correlation with serum copper levels.
    Sirsat AV; Raste AS; Talavdekar RV; Advani SH
    Indian J Cancer; 1979 Jun; 16(2):32-4. PubMed ID: 546729
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum copper content and ceruloplasmin activity in children with lymphogranulomatosis].
    Dmitrieva LV
    Vopr Okhr Materin Det; 1967 Feb; 12(2):37-40. PubMed ID: 5611374
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum levels of ceruloplasmin, properdin factor B and copper in lymphoma patients.
    Casamassima A; Addabbo L; Caporusso L; Lorusso V
    Int J Biol Markers; 1991; 6(3):183-7. PubMed ID: 1791312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum copper is associated with reduced immune response in aging mice.
    Massie HR; Ofosu-Appiah W; Aiello VR
    Gerontology; 1993; 39(3):136-45. PubMed ID: 8406056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavior and prognostic significance of serum ceruloplasmin in relation to the histopathological aspect of Hodgkin's disease].
    Pisi E; Di Feliciantonio R; Figus E; Ferri S
    Minerva Med; 1968 Feb; 59(17):944-52. PubMed ID: 5652623
    [No Abstract]   [Full Text] [Related]  

  • 8. Ceruloplasmin in Hodgkin's disease.
    Koprivová H; Dienstbier Z; Sámal M; Foltýnová V
    Neoplasma; 1982; 29(3):333-40. PubMed ID: 7133228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged observations on variations in the serum copper in Hodgkin's disease.
    Warren RL; Jelliffe AM; Watson JV; Hobbs CB
    Clin Radiol; 1969 Jul; 20(3):247-56. PubMed ID: 5808043
    [No Abstract]   [Full Text] [Related]  

  • 10. Impaired autologous mixed lymphocyte reactivity in Hodgkin's disease.
    Begemann M; Claas G; Falke H
    Klin Wochenschr; 1982 Jan; 60(1):19-26. PubMed ID: 6210797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suggested mode of action of D-penicillamine as an immunosuppressive agent in rheumatoid arthritis.
    Lipsky PE
    Z Rheumatol; 1988; 47 Suppl 1():6-8. PubMed ID: 2975107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes.
    Lipsky PE
    J Clin Invest; 1984 Jan; 73(1):53-65. PubMed ID: 6606652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sera from patients with Hodgkin's disease on normal lymphocyte response to phytohemagglutinin.
    Han T
    Cancer; 1972 Jun; 29(6):1626-31. PubMed ID: 5031250
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical usefulness of serum copper determinations in Hodgkin's disease. A retrospective study of 241 patients from 1963-1973.
    Thorling EB; Thorling K
    Cancer; 1976 Jul; 38(1):225-31. PubMed ID: 947517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of laboratory indicators in Hodgkin's disease: preliminary results.
    Ray GR; Wolf PH; Kaplan HS
    Natl Cancer Inst Monogr; 1973 May; 36():315-23. PubMed ID: 4744591
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of quadruple chemotherapy on the peripheral blood lymphocyte populations in Hodgkin's disease.
    Clay A; Swain A; Trounce JR
    Br J Clin Pharmacol; 1977 Aug; 4(4):475-8. PubMed ID: 901740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum ferritin and other biological parameters as indicators of tumor activity in Hodgkin's disease].
    Hermosa V; Mazo E; Baró J; Castillo E; Cordovilla JJ; Carril J; Zubizarreta A
    Sangre (Barc); 1985; 30(2):154-8. PubMed ID: 2409612
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lymphocytes and Hodgkin's disease. Study of crossing and blastogenesis].
    Cavallero P; Sartoris S; Vergnano F
    Minerva Med; 1972 Sep; 63(60):3255-7. PubMed ID: 5054008
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical significance of the blood copper in Hodgkin's disease.
    PAGLIARDI E; GIANGRANDI E
    Acta Haematol; 1960 Oct; 24():201-12. PubMed ID: 13732060
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blood copper and ceruloplasmin levels in hemolymphopathies. I. Malignant lymphoma].
    Tura S; Bernardi L; Baccarani M; Sanguinetti F; Branzi A
    G Clin Med; 1968 Nov; 49(11):1090-104. PubMed ID: 5757473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.